Search company, investor...

Predict your next investment

Venture Capital
5amventures.com

Investments

228

Portfolio Exits

53

Funds

9

Partners & Customers

1

Service Providers

1

About 5AM Ventures

5AM Ventures is a seed and early-stage venture capital firm focused on building life science companies. 5AM Ventures was founded in 2002 and is based in San Francisco, California.

Headquarters Location

501 Second Street Suite 350

San Francisco, California, 94107,

United States

415-993-8570

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest 5AM Ventures News

Nouscom Raises €67.5m in Series C Financing

Nov 14, 2023

Nouscom , a Basel, Switzerland-based clinical stage immuno-oncology company, raised €67.5M in Series C funding. The round was led by Andera Partners, Bpifrance (through its InnoBio 2 fund) and M Ventures, with participation from Revelation Partners, Indaco Venture Partners, Panakès Partners, XGen Ventures, and existing investors 5AM Ventures, EQT Life Sciences and Versant Ventures. Concurrent with the financing, representatives from Andera Partners, Bpifrance and M Ventures have joined the Nouscom Board of Directors. The company intends to use the funds to continue advancing and expanding its wholly owned clinical pipeline to achieve multiple clinical value catalysts, including: Readout from its ongoing randomized Phase 2 clinical trial for NOUS-209, an off-the-shelf vaccine targeting 209 shared neoantigens, in combination with pembrolizumab for the treatment of Mismatch Repair/Microsatellite Instable (dMMR/MSI) Metastatic Colorectal Cancer (mCRC). Final readout from the ongoing Phase 1b study and advancement of NOUS-209 monotherapy in Lynch Syndrome (LS) carriers investigating the potential to intercept, prevent or delay cancer before it occurs. LS carriers have a genetic predisposition to and consequently higher risk of developing certain cancers. Promising initial results from this study were reported in a Late-breaking Abstract at the recent Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting. Completion of a Phase 1b study evaluating NOUS-PEV, a personalized cancer immunotherapy, in combination with a checkpoint inhibitor in patients with advanced melanoma and entry into randomized Phase 2 trials in indications with high unmet medical needs. Led by CEO Marina Udier, Nouscom is a clinical-stage immuno-oncology company developing off-the-shelf and personalized cancer immunotherapies. Its proprietary viral vector platform has the capacity to encode for large payloads of neoantigens or other immunomodulators and clinically demonstrated to safely and potently of the immune system. Nouscom has also exclusively out-licensed VAC-85135, an off-the-shelf immunotherapy developed under a multi-project agreement, which is currently under evaluation in a Phase 1 trial for the treatment of Myeloproliferative Neoplasms sponsored by Janssen Research & Development and Bristol Myers Squibb. FinSMEs 14/11/2023

5AM Ventures Investments

228 Investments

5AM Ventures has made 228 investments. Their latest investment was in Nouscom as part of their Series C on November 11, 2023.

CBI Logo

5AM Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/14/2023

Series C

Nouscom

$72M

No

3

10/5/2023

Series A

Precede Biosciences

$57M

No

2

9/13/2023

Seed VC

Nvelop Therapeutics

Yes

Atlas Venture, F-Prime Capital, Newpath Partners, and Undisclosed Investors

3

8/21/2023

PIPE

Subscribe to see more

$99M

Subscribe to see more

10

8/14/2023

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/14/2023

10/5/2023

9/13/2023

8/21/2023

8/14/2023

Round

Series C

Series A

Seed VC

PIPE

Series A - II

Company

Nouscom

Precede Biosciences

Nvelop Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$72M

$57M

$99M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Atlas Venture, F-Prime Capital, Newpath Partners, and Undisclosed Investors

Sources

3

2

3

10

10

5AM Ventures Portfolio Exits

53 Portfolio Exits

5AM Ventures has 53 portfolio exits. Their latest portfolio exit was Dianthus Therapeutics on September 11, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/11/2023

Reverse Merger

$99M

4

8/21/2023

Acquired

$99M

2

7/18/2023

IPO

$99M

Public

4

2/23/2023

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

12/29/2022

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/11/2023

8/21/2023

7/18/2023

2/23/2023

12/29/2022

Exit

Reverse Merger

Acquired

IPO

Reverse Merger

Reverse Merger

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

4

2

4

10

10

5AM Ventures Acquisitions

1 Acquisition

5AM Ventures acquired 1 company. Their latest acquisition was Borean Pharma on January 15, 2008.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/15/2008

Series B

$99M

$18.46M

Asset Sale

1

Date

1/15/2008

Investment Stage

Series B

Companies

Valuation

$99M

Total Funding

$18.46M

Note

Asset Sale

Sources

1

5AM Ventures Fund History

9 Fund Histories

5AM Ventures has 9 funds, including 5AM Ventures VII.

Closing Date

Fund

Fund Type

Status

Amount

Sources

4/4/2022

5AM Ventures VII

$450M

1

4/4/2022

5AM Opportunities II

$99M

10

2/13/2019

5AM Ventures VI

Subscribe to see more

Subscribe to see more

$99M

10

2/13/2019

5AM Opportunities I

Subscribe to see more

Subscribe to see more

$99M

10

5/27/2016

5AM Ventures V

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

4/4/2022

4/4/2022

2/13/2019

2/13/2019

5/27/2016

Fund

5AM Ventures VII

5AM Opportunities II

5AM Ventures VI

5AM Opportunities I

5AM Ventures V

Fund Type

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$450M

$99M

$99M

$99M

$99M

Sources

1

10

10

10

10

5AM Ventures Partners & Customers

1 Partners and customers

5AM Ventures has 1 strategic partners and customers. 5AM Ventures recently partnered with Scientist.com on June 6, 2019.

Date

Type

Business Partner

Country

News Snippet

Sources

6/2/2019

Partner

United States

Scientist.com Partners With 5AM Ventures to Create an R&D Marketplace for Biotech Startups

SAN DIEGO -- -- Scientist.com , the world 's largest marketplace for outsourced R&D services , today announced a partnership with 5AM Ventures , a leading venture capital firm focused on building next-generation life science companies .

1

Date

6/2/2019

Type

Partner

Business Partner

Country

United States

News Snippet

Scientist.com Partners With 5AM Ventures to Create an R&D Marketplace for Biotech Startups

SAN DIEGO -- -- Scientist.com , the world 's largest marketplace for outsourced R&D services , today announced a partnership with 5AM Ventures , a leading venture capital firm focused on building next-generation life science companies .

Sources

1

5AM Ventures Service Providers

1 Service Provider

5AM Ventures has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

General Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

General Counsel

Partnership data by VentureSource

5AM Ventures Team

15 Team Members

5AM Ventures has 15 team members, including current Founder, Managing Partner, Andrew J. Schwab.

Name

Work History

Title

Status

Andrew J. Schwab

Bay City Capital, Montgomery, and Aravis Ventures

Founder, Managing Partner

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Andrew J. Schwab

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Bay City Capital, Montgomery, and Aravis Ventures

Title

Founder, Managing Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.